Effects of endotoxin on lactate metabolism in humans.
Critical Care, July 2012
Michaeli B, Martinez A, Revelly JP, Cayeux MC, Chiolero RL, Tappy L, Berger MM, Burkhard Michaeli, Alexandre Martinez, Jean-Pierre Revelly, Marie-Christine Cayeux, René L Chioléro, Luc Tappy, Mette M Berger
ABSTRACT: INTRODUCTION: Hyperlactatemia represents one prominent component of the metabolic response to sepsis. In critically ill patients, hyperlactatemia is related to the severity of the underlying condition. Both an increased production and a decreased utilization and clearance might be involved in this process, but their relative contribution remains unknown. The present study aimed at assessing systemic and muscle lactate production and systemic lactate clearance in healthy human volunteers, using intravenous endotoxin (LPS) challenge. METHODS: Fourteen healthy male volunteers were enrolled in 2 consecutive studies (n = 6 in trial 1 and n = 8 in trial 2). Each subject took part in one of two investigation days (LPS-day with endotoxin injection and placebo-day with saline injection) separated by one week at least and in a random order. In trial 1, their muscle lactate metabolism was monitored using microdialysis. In trial 2, their systemic lactate metabolism was monitored by means of a constant infusion of exogenous lactate. Energy metabolism was monitored by indirect calorimetry and glucose kinetics was measured with 6,6-H2 glucose. RESULTS: In both trials, LPS increased energy expenditure (p = 0.011), lipid oxidation (p<0.0001), and plasma lactate concentration (p = 0.016). In trial 1, lactate concentration in the muscle microdialysate was higher than in blood, indicating lactate production by muscles. This was, however, similar with and without LPS. In trial 2, calculated systemic lactate production increased after LPS (p = 0.031), while lactate clearance remained unchanged. CONCLUSIONS: LPS administration increases lactatemia by increasing lactate production rather than by decreasing lactate clearance. Muscle is, however, unlikely to be a major contributor to this increase in lactate production. TRIAL REGISTRATION: ClinicalTrials.gov NCT01647997.
|Members of the public||1||100%|
|Readers by professional status||Count||As %|
|Student > Ph. D. Student||13||17%|
|Student > Doctoral Student||9||12%|
|Student > Postgraduate||9||12%|
|Student > Bachelor||9||12%|
|Readers by discipline||Count||As %|
|Medicine and Dentistry||52||67%|
|Agricultural and Biological Sciences||5||6%|
|Biochemistry, Genetics and Molecular Biology||4||5%|
|Nursing and Health Professions||2||3%|
|Pharmacology, Toxicology and Pharmaceutical Science||2||3%|